Patents by Inventor Kazunori Hirayama

Kazunori Hirayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11915765
    Abstract: A semiconductor storage device includes a memory cell array, a peripheral circuit configured to perform writing of data to the memory cell array and reading of data from the memory cell array, and a sampling circuit configured to execute a sampling process by which sampling data is collected from a predetermined node of the peripheral circuit, during a period in which the peripheral circuit performs the writing of data to the memory cell array or the reading of data from the memory cell array.
    Type: Grant
    Filed: November 2, 2022
    Date of Patent: February 27, 2024
    Assignee: Kioxia Corporation
    Inventor: Kazunori Hirayama
  • Patent number: 11679166
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: June 20, 2023
    Assignee: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
  • Patent number: 11667724
    Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: June 6, 2023
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Hitoshi Doihara, Kazunori Hirayama, Hiroki Shirai
  • Publication number: 20230047685
    Abstract: A semiconductor storage device includes a memory cell array, a peripheral circuit configured to perform writing of data to the memory cell array and reading of data from the memory cell array, and a sampling circuit configured to execute a sampling process by which sampling data is collected from a predetermined node of the peripheral circuit, during a period in which the peripheral circuit performs the writing of data to the memory cell array or the reading of data from the memory cell array.
    Type: Application
    Filed: November 2, 2022
    Publication date: February 16, 2023
    Inventor: Kazunori HIRAYAMA
  • Patent number: 11521685
    Abstract: A semiconductor storage device includes a memory cell array, a peripheral circuit configured to perform writing of data to the memory cell array and reading of data from the memory cell array, and a sampling circuit configured to execute a sampling process by which sampling data is collected from a predetermined node of the peripheral circuit, during a period in which the peripheral circuit performs the writing of data to the memory cell array or the reading of data from the memory cell array.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: December 6, 2022
    Assignee: KIOXIA CORPORATION
    Inventor: Kazunori Hirayama
  • Publication number: 20220096653
    Abstract: Provided is a conjugate comprising a ligand, a spacer, and a peptide linker useful for an in-vivo diagnostic drug and internal radiation therapy, using an anti-human CEACAM5 antibody Fab fragment whose binding activity is not attenuated even by labeling with a metal, a fluorescent dye, or the like. A conjugate comprising an anti-human CEACAM5 antibody Fab fragment and a ligand, the fragment comprising a heavy chain fragment including a heavy chain variable region consisting of a specific amino acid sequence and a light chain including a light chain variable region consisting of a specific amino acid sequence, or a conjugate comprising a ligand, a spacer, and a peptide linker, wherein the binding activity thereof is not attenuated even by labeling with a metal, a fluorescent dye, or the like, can be used as a diagnostic composition and/or a pharmaceutical composition.
    Type: Application
    Filed: January 6, 2020
    Publication date: March 31, 2022
    Inventors: Michinori Akaiwa, Junya Ishida, Hiroki Toya, Nobuyuki Shiraishi, Toru Asano, Tomoaki Yoshikawa, Yorikata Sano, Hitoshi Doihara, Hiroki Shirai, Kazunori Hirayama
  • Publication number: 20220013175
    Abstract: A semiconductor storage device includes a memory cell array, a peripheral circuit configured to perform writing of data to the memory cell array and reading of data from the memory cell array, and a sampling circuit configured to execute a sampling process by which sampling data is collected from a predetermined node of the peripheral circuit, during a period in which the peripheral circuit performs the writing of data to the memory cell array or the reading of data from the memory cell array.
    Type: Application
    Filed: February 24, 2021
    Publication date: January 13, 2022
    Inventor: Kazunori HIRAYAMA
  • Publication number: 20210340276
    Abstract: Provided are a conjugate comprising an anti-human MUC1 antibody Fab fragment and a peptide linker and/or a ligand, a composition for diagnosis and/or a pharmaceutical composition comprising the conjugate, a method for diagnosing and/or treating a cancer using the conjugate, and the like. In the conjugate used, the anti-human MUC1 antibody Fab fragment is bound to the ligand via the peptide linker or the like.
    Type: Application
    Filed: May 17, 2019
    Publication date: November 4, 2021
    Applicant: Astellas Pharma Inc.
    Inventors: Toru ASANO, Yorikata SANO, Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Michinori AKAIWA, Hiroyoshi YAMADA, Nobuyuki SHIRAISHI
  • Publication number: 20200261603
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: November 12, 2019
    Publication date: August 20, 2020
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
  • Publication number: 20200171174
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: November 14, 2019
    Publication date: June 4, 2020
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
  • Publication number: 20200123270
    Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: July 6, 2018
    Publication date: April 23, 2020
    Inventors: Hitoshi Doihara, Kazunori Hirayama, Hiroki Shirai
  • Patent number: 10517966
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 31, 2019
    Assignee: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
  • Patent number: 10507251
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: December 17, 2019
    Assignee: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
  • Publication number: 20190307906
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: November 17, 2017
    Publication date: October 10, 2019
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
  • Publication number: 20190269804
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara